Despite our improved understanding of pancreatic cancer biology and ability to perform
more complex pancreatic cancer surgeries that produce better short-term outcomes, major …

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical
resection is a requirement for a potential cure. However, the majority of patients are …

The burden of cancer is growing, and the disease is becoming a major economic
expenditure for all developed countries. In 2008, the worldwide cost of cancer due to …

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …

Comparative Effectiveness and Health Care Spending — Implications for Reform | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

Metastatic pancreatic cancer is one of the most aggressive and highly lethal malignancies,
with an estimated 5-year survival of less than 5%. In 2013, approximately 45,000 new cases …

Summary Background Axitinib (AG-013736) is a potent and selective oral inhibitor of
vascular endothelial growth factor receptors 1, 2, and 3, which have an important role in …

The prognosis of patients with pancreatic cancer is extremely poor, and current systemic
therapies provide marginal survival benefits for treated patients. The era of targeted …

Background Statins have potential antineoplastic properties via arrest of cell-cycle
progression and induction of apoptosis. A previous study demonstrated in vitro and in vivo …

Abstract The 4-anilinoquinazolines (gefitinib, erlotinib and lapatinib) are members of a class
of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family …